+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Impact on prognosis of periprocedural myocardial infarction after percutaneous coronary intervention

Impact on prognosis of periprocedural myocardial infarction after percutaneous coronary intervention

Journal of Interventional Cardiology 27(5): 482-490

Different definitions of periprocedural myocardial infarction (MI) after percutaneous coronary intervention (PCI) have been provided, but their impact on prognosis remains to be determined. Procedural data from consecutive patients undergoing PCI from 2009 to 2011 were revised to adjudicate diagnosis of periprocedural MI according to CK-MB increase (>3 × URL and >5 × URL), to troponin increase (>3 × 99th percentile URL and >5 × 99th percentile URL) and to recent 2012 Task Force and Society for Cardiovascular Angiography and Interventions (SCAI) definitions. Major adverse cardiovascular events (MACE) was the primary end-point. Seven hundred twelve patients were enrolled; after 771 days, 115 (16.7%) patients experienced MACE. One hundred ninety patients were diagnosed with a periprocedural MI defined as elevation of troponin >5 × 99th percentile of URL. When adjudicating 2012 Task Force definition on these patients, 46 were excluded and 1.4% of them experienced a MACE and 0.3% died, while among 144 with periprocedural MI, 2.9% reported a MACE and 1.3% died. After appraisal of SCAI definition, 176 patients were excluded, 3.8% of them with a MACE and 1.4% died, and for those with periprocedural MI, 0.5% experienced a MACE and 0.1% died. Similar low performance was appraised after reclassification of patients from more than 3 of upper limit of CK-MB and of troponin. At multivariate analysis, none of these definitions related to adverse events. Periprocedural MI represents a frequent complication for patients undergoing PCI. All present definitions share a still not satisfactory discrimination between patients with and without adverse events at follow-up, stressing the need for more accurate definitions.

(PDF emailed within 0-6 h: $19.90)

Accession: 053727651

Download citation: RISBibTeXText

PMID: 25175019

DOI: 10.1111/joic.12143

Related references

Impact of coronary plaque burden and composition on periprocedural myocardial infarction and coronary flow reserve after percutaneous coronary intervention. International Heart Journal 55(5): 391-396, 2014

Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. European Heart Journal 25(20): 1822-1828, 2004

Statin administration before percutaneous coronary intervention: Impact on periprocedural myocardial infarction. Acc Current Journal Review 14(2): 45-0, 2005

Impact of crossing technique on the incidence of periprocedural myocardial infarction during chronic total occlusion percutaneous coronary intervention. Catheterization and Cardiovascular Interventions 88(1): 1-6, 2017

Impact of large periprocedural myocardial infarction on mortality after percutaneous coronary intervention and coronary artery bypass grafting for left main disease: an analysis from the EXCEL trial. European Heart Journal 2019, 2019

TCT-671 Clinical impact of periprocedural myocardial infarction according to various definitions in patients underwent percutaneous coronary intervention with drug eluting stent. Journal of the American College of Cardiology 70(18): B293-B294, 2017

The prognosis of periprocedural myocardial infarction after percutaneous coronary interventions. Cardiovascular Revascularization Medicine 14(1): 32-36, 2013

Impact of statins preloading before PCI on periprocedural myocardial infarction among stable angina pectoris patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. Cardiovascular Revascularization Medicine 2018, 2018

Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry. Jacc. Cardiovascular Interventions 2(11): 1074-1082, 2010

Coronary plaque morphology on multi-modality imagining and periprocedural myocardial infarction after percutaneous coronary intervention. International Journal of Cardiology. Heart and Vasculature 11: 43-48, 2016

Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. Journal of the American College of Cardiology 55(20): 2201-2209, 2010

Statin loading before percutaneous coronary intervention to reduce periprocedural myocardial infarction. Cardiology in Review 20(6): 319-324, 2013

Detecting Periprocedural Myocardial Infarction in Contemporary Percutaneous Coronary Intervention Trials. Jacc. Cardiovascular Interventions 10(7): 658-666, 2017

Effect on periprocedural myocardial infarction of intra-coronary nicorandil prior to percutaneous coronary intervention in stable and unstable angina. Journal of Cardiology 62(2): 77-81, 2014

Coronary artery calcium score in predicting periprocedural myocardial infarction in patients undergoing an elective percutaneous coronary intervention. Coronary Artery Disease 29(7): 589-596, 2018